BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

Analyst Reco. Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Market Closed - Nyse Other stock markets 04:00:02 2024-05-10 pm EDT			5-day change	1st Jan Change
35.69 ^USD	-13.71%		-12.29%	-76.49%

May. 10	Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates	MT
Apr. 25	Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	Apr. 25	MT
UBS Adjusts Biohaven Price Target to $60 From $59, Maintains Buy Rating	Apr. 23	MT
Biohaven Launches $200 Million Common Stock Offering	Apr. 17	MT
HC Wainwright Adjusts Biohaven's Price Target to $63 From $50, Maintains Buy Rating	Mar. 04	MT
TD Cowen Ups Price Target on Biohaven to $55 From $35, Keeps Outperform Rating	Mar. 01	MT
RBC Trims Price Target on Biohaven to $61 From $62, Keeps Outperform, Speculative Risk	Mar. 01	MT
RBC Initiates Biohaven at Outperform With Speculative Risk, Sets Price Target at $62, Sees 'Significant Value to Be Unlocked' Over Long Term	Feb. 16	MT
UBS Adjusts Initiates Biohaven Pharmaceutical Holding With Buy Rating, $59 Price Target	Feb. 06	MT
Baird Starts Biohaven Pharmaceutical With Outperform Rating, $58 Price Target	Dec. 08	MT
JPMorgan Adjusts Biohaven Pharmaceutical Price Target to $32 From $26, Maintains Overweight Rating	Nov. 20	MT
Piper Sandler Adjusts Price Target on Biohaven Pharmaceutical to $36 From $29, Keeps Overweight Rating	Nov. 15	MT
JPMorgan Adjusts Price Target on Biohaven Pharmaceutical Holding to $24 From $27, Maintains Overweight Rating	23-08-16	MT
Cantor Fitzgerald Raises Price Target on Biohaven Pharmaceutical to $31 From $27, Maintains Overweight Rating	23-04-04	MT
SVB Leerink Initiates Biohaven at Outperform With $24 Price Target	23-01-24	MT
JPMorgan Starts Biohaven Pharmaceutical Holding at Overweight With $23 Price Target	23-01-04	MT
BTIG Starts Biohaven Pharmaceutical Holding at Buy With $24 Price Target	22-12-02	MT
William Blair Initiates Biohaven Pharmaceutical Holding Company With Outperform Rating	22-11-10	MT
Piper Sandler Adjusts Price Target on Biohaven Pharmaceutical to $21 From $23, Reiterates Overweight Rating	22-10-26	MT
Piper Sandler Initiates Biohaven at Overweight with $23 Price Target	22-10-12	MT
Piper Sandler Downgrades Biohaven Pharmaceutical to Neutral From Overweight, Maintains $149 Price Target	22-08-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Analyst Reco.

Filters